Earnings results for Sun BioPharma (NASDAQ:SNBP)
Sun BioPharma, Inc. is expected* to report earnings on 11/12/2020 after market close. The report will be for the fiscal Quarter ending Sep 2020.
Analyst Opinion on Sun BioPharma (NASDAQ:SNBP)
1 Wall Street analysts have issued ratings and price targets for Sun BioPharma in the last 12 months. Their average twelve-month price target is $9.00, predicting that the stock has a possible upside of 183.91%. The high price target for SNBP is $9.00 and the low price target for SNBP is $9.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of “Buy.”
Sun BioPharma has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $9.00, Sun BioPharma has a forecasted upside of 183.9% from its current price of $3.17. Sun BioPharma has only been the subject of 1 research reports in the past 90 days.
Dividend Strength: Sun BioPharma (NASDAQ:SNBP)
Sun BioPharma does not currently pay a dividend. Sun BioPharma does not have a long track record of dividend growth.
Insiders buying/selling: Sun BioPharma (NASDAQ:SNBP)
In the past three months, Sun BioPharma insiders have not sold or bought any company stock. Only 30.00% of the stock of Sun BioPharma is held by insiders.
Earnings and Valuation of Sun BioPharma (NASDAQ:SNBP
More latest stories: here